ES2123756T3 - Derivados de piperazina. - Google Patents

Derivados de piperazina.

Info

Publication number
ES2123756T3
ES2123756T3 ES94903945T ES94903945T ES2123756T3 ES 2123756 T3 ES2123756 T3 ES 2123756T3 ES 94903945 T ES94903945 T ES 94903945T ES 94903945 T ES94903945 T ES 94903945T ES 2123756 T3 ES2123756 T3 ES 2123756T3
Authority
ES
Spain
Prior art keywords
pct
date
sec
aryl
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94903945T
Other languages
English (en)
Inventor
Ian Anthony Cliffe
Christopher BRIGHTWELL
Howard Mansell
Alan White
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
John Wyeth and Brother Ltd
Original Assignee
John Wyeth and Brother Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by John Wyeth and Brother Ltd filed Critical John Wyeth and Brother Ltd
Application granted granted Critical
Publication of ES2123756T3 publication Critical patent/ES2123756T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/40—Nitrogen atoms attached in position 8
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Quinoline Compounds (AREA)
  • Indole Compounds (AREA)
  • Polymers With Sulfur, Phosphorus Or Metals In The Main Chain (AREA)

Abstract

LOS DERIVADOS DE PIPERAZINAS DE LA FORMULA (I) Y SUS SALES FARMACEUTICAMENTE ACEPTABLES SON AGENTES AGLUTINANTES DE 5HT{SUB,1A} Y SE PUEDEN UTILIZAR, POR EJEMPLO, A MODO DE ANSIOLITICOS. EN LA FORMULA, A ES UNA CADENA DE ALQUILENO OPCIONALMENTE SUSTITUIDA, Z ES UN NITROGENO BICICLICO ESPECIFICO QUE CONTIENE UN RADICAL HETEROAROMATICO, R ES HIDROGENO O ALQUILO INFERIOR, R{SUB,1} ES ARILO O ARILALQUILO (INFERIOR) Y R{SUB,2} Y R{SUB,3} SON HIDROGENO O RADICALES ORGANICOS ESPECIFICOS O NR{SUB,2}R{SUB,3} REPRESENTA UN ANILLO HETEROCICLICO.
ES94903945T 1993-01-06 1993-12-24 Derivados de piperazina. Expired - Lifetime ES2123756T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB939300195A GB9300195D0 (en) 1993-01-06 1993-01-06 Piperazine derivatives

Publications (1)

Publication Number Publication Date
ES2123756T3 true ES2123756T3 (es) 1999-01-16

Family

ID=10728387

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94903945T Expired - Lifetime ES2123756T3 (es) 1993-01-06 1993-12-24 Derivados de piperazina.

Country Status (14)

Country Link
US (1) US5627177A (es)
EP (1) EP0678090B1 (es)
JP (1) JPH08505156A (es)
AT (1) ATE172193T1 (es)
AU (1) AU5819794A (es)
DE (1) DE69321609T2 (es)
DK (1) DK0678090T3 (es)
ES (1) ES2123756T3 (es)
GB (1) GB9300195D0 (es)
IL (1) IL108258A (es)
MX (1) MX9400253A (es)
MY (1) MY131381A (es)
PH (1) PH31303A (es)
WO (1) WO1994015919A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5434158A (en) * 1994-04-26 1995-07-18 Merck & Co., Inc. Spiro-substituted azacycles as neurokinin-3 antagonists
GB9411099D0 (en) * 1994-06-03 1994-07-27 Wyeth John & Brother Ltd Piperazine derivatives
CA2194984C (en) 1994-07-26 2002-07-02 John Eugene Macor 4-indole derivatives as serotonin agonists and antagonists
GB9419024D0 (en) * 1994-09-21 1994-11-09 Wyeth John & Brother Ltd Bicyclic carboxamides
US5607936A (en) * 1994-09-30 1997-03-04 Merck & Co., Inc. Substituted aryl piperazines as neurokinin antagonists
FR2735127B1 (fr) * 1995-06-09 1997-08-22 Pf Medicament Nouvelles piperazines heteroaromatiques utiles comme medicaments.
US5990114A (en) * 1996-02-28 1999-11-23 Recordati, S.A., Chemical And Pharmaceutical Company Use of 5-HT1A receptor antagonists for the treatment of urinary incontinence
DE69819266T2 (de) * 1997-09-02 2004-07-29 Duphar International Research B.V. Piperidin- und Piperazin Derivate als 5-HT1-Rezeptor-Agonisten
EP0900792B1 (en) * 1997-09-02 2003-10-29 Duphar International Research B.V Piperazine and piperidine derivatives as 5-HT1A and dopamine D2-receptor (ant)agonists
AR019178A1 (es) * 1998-06-30 2001-12-26 Lilly Co Eli Compuestos de 7-(benzo(b)tiofeno, furan e indolpiridil o tetrahidropiridilo), efectivos sobre sistemas relacionados con la serotonina, composicionesfarmaceuticas formuladas con dichos compuestos; compuestos intermediarios utiles para preparar dichos compuestos de tiofeno, furan e indolpiridilo otetr
US6743796B2 (en) 2001-05-07 2004-06-01 Wyeth Piperazinyl-isatins
ITMI20021327A1 (it) * 2002-06-14 2003-12-15 Recordati Chem Pharm Nuove ossialchilpiperazine
US7071197B2 (en) * 2002-06-14 2006-07-04 Recordati S.A. N,N-disubstituted diazocycloalkanes
US20040072839A1 (en) * 2002-06-14 2004-04-15 Amedeo Leonardi 1-Phenylalkylpiperazines
GB0316915D0 (en) 2003-07-18 2003-08-20 Glaxo Group Ltd Compounds

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL94151A (en) * 1989-04-22 1995-08-31 Wyeth John & Brother Ltd History of piperazine, their preparation and pharmaceutical preparations containing them
EP0955296A3 (en) * 1989-04-22 2000-01-19 American Home Products Corporation Tertiary alkyl functionalized piperazine derivatives
US5382583A (en) * 1989-04-22 1995-01-17 John Wyeth & Brother, Limited Piperazine derivatives
DK203990D0 (da) * 1990-08-24 1990-08-24 Novo Nordisk As Piperazinylderivater
GB9022821D0 (en) * 1990-10-19 1990-12-05 Wyeth John & Brother Ltd Piperazine derivatives
MX9201991A (es) * 1991-05-02 1992-11-01 Jonh Wyeth & Brother Limited Derivados de piperazina y procedimiento para su preparacion.
GB9125900D0 (en) * 1991-12-05 1992-02-05 Wyeth John & Brother Ltd Piperazine derivatives

Also Published As

Publication number Publication date
DK0678090T3 (da) 1999-06-23
GB9300195D0 (en) 1993-03-03
DE69321609T2 (de) 1999-03-25
WO1994015919A1 (en) 1994-07-21
JPH08505156A (ja) 1996-06-04
EP0678090A1 (en) 1995-10-25
ATE172193T1 (de) 1998-10-15
DE69321609D1 (de) 1998-11-19
IL108258A0 (en) 1994-04-12
MY131381A (en) 2007-08-30
US5627177A (en) 1997-05-06
IL108258A (en) 1998-12-06
EP0678090B1 (en) 1998-10-14
MX9400253A (es) 1994-08-31
PH31303A (en) 1998-07-06
AU5819794A (en) 1994-08-15

Similar Documents

Publication Publication Date Title
DK0677046T3 (da) Piperazinderivater som 5-HT-antagonister.
DK0678090T3 (da) Piperazinderivater
MY107756A (en) Piperazine derivatives.
ATE275134T1 (de) 4-oxo-1,4-dihydro-3-chinolincarboxamide als antivirale mittel
DK0625977T3 (da) Piperazinderivater som 5-1A-antagonister
NO972938D0 (no) Farmasöytiske piperazinforbindelser
GB9306103D0 (en) Piperazine derivatives
DE69431471D1 (de) Amide derivate als 5-ht1a liganden
TW257758B (en) Piperazine derivatives (1)
KR970706280A (ko) 5-HT1A 길항제로서의 비사이클릭 카복스아미드(Bicyclic carboxamides as 5-HT1 antagonists)
DE69403896D1 (de) 4-amino-2-(hetero)aryl-butanamide verwenbar als 5-ht1a-antagonisten

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 678090

Country of ref document: ES